Correlation between dynamic susceptibility contrast perfusion MRI and methionine metabolism in brain gliomas: Preliminary results

To evaluate in brain gliomas the relationship between tumor vascularity measured by MR‐based maximum regional cerebral blood volume (rCBV) and tumor amino‐acid metabolism based on maximum carbon‐11 methionine (MET) uptake on positron emission tomography (PET).

[1]  Karl Herholz,et al.  Methyl-[11C]-l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  B. Rosen,et al.  Microscopic susceptibility variation and transverse relaxation: Theory and experiment , 1994, Magnetic resonance in medicine.

[3]  M. Schwaiger,et al.  Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  D. Comar,et al.  Labelling and metabolism of methionine-methyl-11C , 2004, European Journal of Nuclear Medicine.

[5]  W. Koch,et al.  Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  D. Hwang,et al.  Prediction of Pathology and Survival by FDG PET in Gliomas , 2003, Journal of Neuro-Oncology.

[7]  J. Duyn,et al.  A. functional MRI technique combining principles of echo‐shifting with a train of observations (PRESTO) , 1993, Magnetic resonance in medicine.

[8]  F. Chapon,et al.  Non-invasive grading of oligodendrogliomas: correlations between in vivo metabolic pattern and histopathology , 2000, European Journal of Nuclear Medicine.

[9]  B. Rosen,et al.  High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[10]  Glyn Johnson,et al.  Relative cerebral blood volume measurements in intracranial mass lesions: interobserver and intraobserver reproducibility study. , 2002, Radiology.

[11]  S. Goldman,et al.  Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. , 2004, Journal of neurosurgery.

[12]  K Wienhard,et al.  Increased amino acid transport into brain tumors measured by PET of L-(2-18F)fluorotyrosine. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  N. Kuwata,et al.  Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining , 1999, Neurosurgical Review.

[14]  E F Halpern,et al.  Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. , 1994, Radiology.

[15]  J Hildebrand,et al.  Positron emission tomography-guided stereotactic brain biopsy. , 1992, Neurosurgery.

[16]  P. Kelly,et al.  Grading of astrocytomas: A simple and reproducible method , 1988, Cancer.

[17]  H Lundqvist,et al.  Comparison of the Accumulation Kinetics of L-(Methyl-11C)-Methionine and D-(Methyl-11C)-Methionine in Brain Tumors Studied with Positron Emission Tomography , 1987, Acta radiologica.

[18]  H. Engler,et al.  Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas. , 2001, Cancer.

[19]  Mark S. Cohen,et al.  Contrast agents and cerebral hemodynamics , 1991, Magnetic resonance in medicine.

[20]  A. Luxen,et al.  Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. , 1995, Journal of neurosurgery.

[21]  Nancy J Fischbein,et al.  Differentiation of low-grade oligodendrogliomas from low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. , 2005, AJNR. American journal of neuroradiology.

[22]  D. Weinberger,et al.  Three-dimensional functional magnetic resonance imaging of human brain on a clinical 1.5-T scanner. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Glyn Johnson,et al.  Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.

[24]  B. Rosen,et al.  Perfusion imaging with NMR contrast agents , 1990, Magnetic resonance in medicine.

[25]  B. Rosen,et al.  Functional Studies of the Human Brain Using High‐speed Magnetic Resonance Imaging , 1991, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[26]  O. Witte,et al.  Positron emission tomography with injection of methionine as a prognostic factor in glioma. , 2001, Journal of neurosurgery.

[27]  E. Cochran,et al.  Oligodendroglioma: pathology and molecular biology. , 2002, Surgical neurology.

[28]  A. Friedman,et al.  Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas , 1991, Neurology.

[29]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[30]  F Shishido,et al.  Cerebral glioma: evaluation with methionine PET. , 1993, Radiology.

[31]  F. Scaravilli,et al.  Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q‐deleted oligodendrogliomas , 2003, Neuropathology and applied neurobiology.

[32]  H. Engler,et al.  Positron emission tomography 11C‐methionine and survival in patients with low‐grade gliomas , 2001 .

[33]  J. Smirniotopoulos.  The new WHO classification of brain tumors. , 1999, Neuroimaging clinics of North America.

[34]  H. P. Richter,et al.  Cranial Neuronavigation with Direct Integration of 11C Methionine Positron Emission Tomography (PET) Data – Results of a Pilot Study in 32 Surgical Cases , 2002, Acta Neurochirurgica.

[35]  M Teräs,et al.  Radiotherapy treatment planning and long-term follow-up with [(11)C]methionine PET in patients with low-grade astrocytoma. , 2000, International journal of radiation oncology, biology, physics.

[36]  B. Rosen,et al.  Susceptibility contrast imaging of cerebral blood volume: Human experience , 1991, Magnetic resonance in medicine.

[37]  Richard A. Baum,et al.  Magnetic Resonance Angiography: Concepts and Applications , 1995 .

[38]  Noninvasive determination of regional cerebral blood flow in rats using dynamic imaging with Gd(DTPA) , 1991, Magnetic resonance in medicine.

[39]  Serge Goldman,et al.  Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[40]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[41]  B. Scheithauer,et al.  The New WHO Classification of Brain Tumours , 1993, Brain pathology.